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Abstract 
Bacterial and fungal infections continue to pose a major clinical challenge in patients with prolonged severe neutro-
penia after chemotherapy or hematopoietic stem cell transplantation (HSCT). With the advent of granulocyte colony-
stimulating factor (G-CSF) to mobilize neutrophils in healthy donors, granulocyte transfusions have been broadly 
used to prevent and/or treat life-threatening infections in patients with severe febrile neutropenia and/or neutrophil 
dysfunction. Although the results of randomized controlled trials are inconclusive, there are suggestions from pilot 
and retrospective studies that granulocyte transfusions may benefit selected categories of patients. We will critically 
appraise the evidence related to the use of therapeutic granulocyte transfusions in children and adults, highlighting 
current controversies in the field and discussing complementary approaches to modulate phagocyte function in the 
host.
Keywords: Granulocyte transfusion, G-CSF, Dexamethasone, Hematopoietic stem cell transplantation, Febrile 
neutropenia, Infection
© 2015 Cugno et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Bacterial and fungal infections remain a significant 
cause of morbidity and mortality in severely neutro-
penic patients with hematological malignancies receiv-
ing dose-intensive chemotherapy and hematopoietic 
stem cell transplantation (HSCT). Once in vogue in the 
1980s, granulocyte transfusions were later relegated to 
a marginal role, due to the inconveniences of harvesting 
cells, infusion-associated toxicities and limited clinical 
efficacy [1]. Several articles offer a historical perspec-
tive on granulocyte transfusions (GTX) and the reader is 
referred to those studies for a thorough overview [1–4]. 
The improved odds of survival shown by clinical trials 
conducted in the 1970s and 1980s may have been related 
to low survival rates of controls, implying that the ben-
efit of adding granulocyte transfusions to contemporary 
treatment protocols for life-threatening infections may 
be questionable [5]. In the early 1990s, the clinical use of 
granulocyte colony-stimulating factor (G-CSF) and the 
advent of leukapheresis reignited the interest in the clini-
cal application of granulocyte transfusions to enhance 
host defenses [3, 6–11]. However, inconsistent clinical 
responses have been documented over the years, likely 
due to differences in patient selection, underlying dis-
order, indications for granulocyte transfusion, e.g., pre-
vention or treatment of infections, type of granulocyte 
concentrates, e.g., related vs. HLA-matched unrelated 
donors, use of G-CSF alone or G-CSF and steroids for 
donor priming, pre-existing alloimmunization or de novo 
development of antibodies against granulocytes, avail-
ability of donors, and treating physicians’ preference [12].
The results of new randomized trials of granulocyte 
transfusions for life-threatening infections have now 
been published. Also, new-generation leukapheresis 
devices have been optimized to further improve the yield 
and purity of granulocyte collections. It thus is an appro-
priate time to review existing data on granulocyte trans-
fusions in neutropenic hosts, and to critically appraise 
the immune-biological effects and safety issues related 
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to G-CSF administration to healthy donors. The follow-
ing PubMed query was used to retrieve relevant clini-
cal trials: (infection OR sepsis) AND (neutropenia OR 
granulocytopenia) AND (“granulocyte transfusion” OR 
“granulocyte transfusions”). We also searched both the 
U.S. National Institutes of Health registry of clinical stud-
ies (http://www.ClinicalTrials.gov) and the International 
Clinical Trials Registry Platform (ICTRP; http://apps.
who.int/trialsearch/).
Neutrophil mobilization
G‑CSF alone or in combination with steroids
The effects of single-dose G-CSF (5–10 µg/kg) on periph-
eral blood counts have been explored in 261 normal sub-
jects donating peripheral blood progenitor cells (PBPC) 
for research. Following G-CSF administration, the neu-
trophil count increased 6.2- to 7.4-fold over baseline val-
ues, depending on G-CSF dose. Sixty-nine percent of the 
donors experienced one or more dose-related side effects 
24 h after G-CSF administration, most commonly muscle 
and bone pain, headache, fatigue and nausea [13].
The combination of G-CSF and dexamethasone has 
been extensively characterized as a granulocyte mobi-
lization regimen. Neutrophilia after single-dose G-CSF 
and dexamethasone is attributed to shifts of neutrophils 
from the bone marrow storage pool into the periph-
eral blood [14]. The analysis of a computerized data-
base containing records of 1198 granulocyte collections 
from 137 unrelated volunteer apheresis donors showed 
that donors with higher neutrophil and platelet counts 
before stimulation have higher neutrophil counts after 
G-CSF and dexamethasone. A uniform G-CSF dose of 
480 μg was equally effective as weight-based dosing at 
5  µg/kg [15]. In another study, 20 donors received oral 
dexamethasone (8 mg) plus a placebo injection, subcuta-
neous G-CSF (5 μg/kg) plus placebo capsules, or G-CSF 
plus dexamethasone. The administration of G-CSF plus 
dexamethasone produced the greatest yields and was 
not associated with increased toxicity as compared with 
G-CSF alone [16].
In a prospective study, 52 healthy unrelated volunteers 
were treated with a single subcutaneous injection of gly-
cosylated G-CSF, lenograstim, at a median dose of 3.1 μg/
kg plus dexamethasone (8  mg orally) or with a median 
dose of 11.8 μg/kg of lenograstim without dexametha-
sone (n  =  23). Mobilization kinetics and leukapheresis 
yields were similar in the low-dose compared with the 
high-dose G-CSF group. Donor adverse reactions were 
of greater clinical significance in donors given high-dose 
G-CSF alone. The combination of glycosylated G-CSF 
and dexamethasone allowed a significant reduction of 
G-CSF dose and enhanced the tolerability of the mobili-
zation regimen to the donors [17].
Another study evaluated the efficacy of four differ-
ent granulocyte mobilization regimens. Donors received 
G-CSF, either intravenously or subcutaneously, with or 
without dexamethasone (8  mg) 18  h before apheresis. 
Whereas G-CSF administration route had no impact on 
neutrophil counts at hours 2 through 8, subcutaneous 
G-CSF and dexamethasone sustained 24-h neutrophil 
counts more effectively than intravenous G-CSF and dex-
amethasone [18].
A possible strategy to minimize the number of donors 
for each patient, thus limiting the risk of alloimmuniza-
tion, would be to use sequential granulocyte collections 
from a single donor given G-CSF daily. This approach 
has been prospectively evaluated in 76 healthy donors, 
who were allowed a maximum of five consecutive dona-
tions [19]. This mobilization schedule translated into a 
continuing increase of white blood cells and neutrophils, 
leading to better collection yields. The side effects related 
to repeat administrations of G-CSF were tolerable, not 
exceeding WHO grade II status. Bone pain, headache, 
arthralgia, and myalgia were commonly observed (24  % 
of the donors), but were transient and responsive to par-
acetamol. Donors who underwent multiple leukapheresis 
procedures gained a median of 1.0  kg of body weight, 
and developed minimal peripheral edema. In one donor, 
a mild skin reaction, likely due to HES, was documented 
on the third day of granulocyte donation [19].
Impact of the mobilization regimen on neutrophil 
phenotype and function
G-CSF has long been recognized as a potent immedi-
ate activator of neutrophils in vivo [20]. An initial study 
in four healthy volunteers given subcutaneous G-CSF 
(300  µg) showed that, shortly post-injection, CD16 was 
upregulated from an intracellular pool. Specific gran-
ules were released, as suggested by increased plasma 
levels of lactoferrin and by upregulation of CD66b and 
CD11b expression on circulating neutrophils. Moreover, 
increased plasma levels of elastase, bound to its physi-
ologic inhibitor α1-antitrypsin, indicated mobilization of 
azurophil granules [20].
The expression of neutrophil antigens has been thor-
oughly evaluated in seven healthy donors receiving 5 μg/
kg of G-CSF for 10 days [21]. The expression of l-selectin 
(CD62L), Fcγ receptor (FcγR) III (FcγRIII, CD16), and 
the leukocyte function antigen (CD11a) decreased dur-
ing the course of G-CSF administration. By contrast, 
FcγRI (CD64) and lipopolysaccharide-binding pro-
tein receptor (CD14) levels increased. The expression 
of amino-peptidase N (CD13), C3bi receptor (CD11b), 
and the neutrophil β2-integrin (CD18) did not change 
during the administration of G-CSF, but levels of both 
CD13 and CD18 increased 3  days after the last dose. 
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Expression levels of neutrophil-specific antigen NB1 
(CD177) initially increased, returned to pre-G-CSF levels 
after 4 days, and increased again after 10 days of G-CSF 
administration. Overall, this study indicated that most 
changes in neutrophil phenotype, potentially affect-
ing the function of mobilized granulocytes, occur after 
one dose of G-CSF. Importantly, the down-regulation of 
CD62L after G-CSF treatment may result from shedding 
and likely limits neutrophil-endothelial cell interactions, 
thus preventing the pulmonary sequestration of granulo-
cytes [21, 22].
Oligonucleotide microarrays were also used to identify 
genes that are differentially expressed before and after 
mobilization with single-dose G-CSF and dexametha-
sone [23]. More than 1000 genes displayed a differential 
expression pattern and, among these, many encoded pro-
teins involved in inflammation and the immune response, 
such as C-type lectins and leukocyte immunoglobulin-
like receptors. These changes could only partly be mim-
icked by in  vitro culture of normal granulocytes with 
100 ng/mL G-CSF and 1 μM dexamethasone, since more 
than 75 % of changes in gene expression were unique to 
in  vivo mobilization with the two drugs. Interestingly, 
transcriptional activity of the CAST gene, which encodes 
calpastatin, was induced after G-CSF/dexamethasone 
treatment both in  vivo and in  vitro. This observation 
may account for the prolonged survival ability imparted 
on granulocytes by the combined treatment with G-CSF 
and dexamethasone. Irrespective of phenotypic changes, 
granulocytes collected after G-CSF and dexamethasone 
benefited 11 out of the 16 children (70  %) who were 
treated with granulocyte transfusions for febrile neutro-
penia [24].
Finally, we pursued a data mining approach to navigate 
publicly available datasets generated in the context of 
G-CSF administration to healthy donors, with the aim at 
identifying differences in transcriptomic profiles of leu-
kocytes from subjects given G-CSF alone or in combina-
tion with steroids. We retrieved three datasets containing 
expression profiling data of leukocytes and monocytes 
from healthy donors receiving G-CSF alone (n  =  2) or 
G-CSF and dexamethasone (n  =  1; http://www.ncbi.
nlm.nih.gov/gds). We identified a priori a panel of genes 
regulating neutrophil effector functions (Table 1) and we 
asked whether their expression was modulated across 
different datasets available from the literature. As shown 
in Fig. 1, the abundance of mRNA transcripts for CD177, 
ELANE, MPO, LYZ, CEACAM8 (CD67), CD64, CD16b, 
and CD62L increased after donor treatment with G-CSF 
[25]. By contrast, SOD1 mRNA expression declined after 
neutrophil mobilization. Compared with G-CSF alone, 
G-CSF and dexamethasone induced a decrease of CD177 
and CD64 mRNA expression (Fig.  2). Interestingly, 
in  vitro exposure of normal neutrophils to G-CSF and 
dexamethasone resulted in a different transcription 
expression profile of our genes of interest, compared 
with in vivo treatment. Specifically, in vitro-treated neu-
trophils failed to up-regulate CD16b, CD62L, ELANE, 
MPO and LYZ mRNA (Fig.  2), suggesting that neutro-
phil phenotype is uniquely influenced by in vivo exposure 
to G-CSF and dexamethasone. Collectively, G-CSF and 
dexamethasone provide advantages over G-CSF alone in 
terms of neutrophil mobilization efficiency and collec-
tion yields. However, further studies are needed to obtain 
insights into the functional changes induced in neutro-
phils by G-CSF in combination with steroids.
Granulocyte collection and storage
Granulocytes for transfusion are usually produced by 
either apheresis or as a component derived from whole 
blood donations [26]. Apheresis allows for the collection 
of large quantities of granulocyte from a single donor 
over a few hours. In order to obtain similar quantities of 
granulocytes from whole blood donations, granulocytes 
obtained from many units of blood must be pooled. For 
apheresis collections, the use of high molecular weight 
hydroxyethyl starch (HES) has been shown to result 
in better granulocyte collection yields, with decreased 
contamination from red blood cells and platelets in the 
granulocyte concentrate [27]. The use of blood cell sepa-
rators to collect granulocytes concentrates by apheresis 
from subjects given G-CSF or G-CSF plus dexametha-
sone has become the standard. However, since there are 
practical difficulties and regulatory requirements for hos-
pitals providing apheresis granulocyte components on 
demand, some groups have recently re-evaluated the use 
of granulocyte components derived from whole blood, 
which can be used as a bridging therapy while identify-
ing suitable apheresis donors, administering mobilizing 
agents and collecting granulocytes by apheresis [26]. A 
standard adult granulocyte component can be derived 
from 20 whole blood donations, providing a daily dose of 
approximately 2 × 1010 granulocytes. The adverse events 
in recipients of granulocytes prepared with this approach 
appear to be comparable to those of recipients of other 
granulocyte components [26].
Cell separation devices
A recent prospective, multicenter, randomized trial com-
pared the performance and safety of a novel granulocyte 
collection protocol with the Spectra Optia® device (Ter-
umo-BCT) to those of the COBE Spectra apheresis sys-
tem (Terumo-BCT) in 32 healthy donors, who received 
G-CSF and dexamethasone. The collection efficiency of 
granulocyte procedures using the Spectra Optia® system 
was approximately 23  % higher than that of the COBE 
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Spectra system. In particular, Spectra Optia® collec-
tions generated a higher total neutrophil yield per liter of 
blood processed compared with the COBE Spectra. No 
differences in granulocyte viability, chemotaxis and bac-
terial killing were evident between the two devices. Not 
unexpectedly, fewer operator adjustments were required 
when using the Spectra Optia®. Importantly, there was 
no difference in the number or intensity of adverse donor 
events between instruments [28].
The Optia device has also been used to collect granu-
locytes from healthy blood donors and family donors 
mobilized with prednisolone or G-CSF. [29]. One study 
showed that the Optia® device is not inferior to the 
COBE Spectra forerunner and produces high-quality 
granulocyte concentrates with greater absolute neutro-
phil yields. In another study, target doses of 1 × 1010 neu-
trophils were achieved in all but one collection with the 
Spectra Optia® device [30]. Again, Spectra Optia® collec-
tions were 20 % more efficient compared with those per-
formed with the predecessor device.
Since the dose of neutrophils transfused is important in 
determining clinical response, the ability to collect higher 
numbers of granulocytes will favorably impact the effi-
cacy of therapeutic granulocyte transfusions.
Neutrophil storage
Although G-CSF and dexamethasone delay granulocyte 
apoptosis, the high cell counts achieved in granulocyte 
concentrates may reduce nutrients and lower pH, result-
ing into neutrophil death. The production of pyrogenic 
cytokines may also be increased. According to current 
standards, granulocyte storage should be limited to 24 h. 
After 2  days of storage in RPMI-1640 medium at 4  °C, 
only 2–7 % of the granulocytes remain viable [31]. Infu-
sible solutions to be used in place of autologous plasma 
have been designed and tested with the aim of improving 
granulocyte storage. For instance, lactated Ringer’s solu-
tion or Plasma-Lyte A supplemented with buffers and 
albumin hold promise as effective and licensable solu-
tions for granulocyte storage [32].
The storage characteristics of granulocyte concentrates 
were compared after mobilization of donors with G-CSF 
and dexamethasone, either alone or in combination [33]. 
Ten granulocyte donors were given oral dexamethasone 
(8 mg), subcutaneous G-CSF (5 μg/kg), or both and gran-
ulocyte concentrates were collected by leukapheresis on 
the next day. Significantly more granulocytes were col-
lected from donors given G-CSF or G-CSF + dexametha-
sone compared with dexamethasone alone. Granulocytes 
mobilized with G-CSF  +  dexamethasone were acidic 
immediately after collection, with pH values declining 
below 6.0 after 24  h. Some increase in IL-1β and IL-8 
was detected after 24 and 48 h as compared to the lev-
els at 2  h storage. By contrast, levels of IL-6 and TNF 
were unchanged. Serial dilutions in autologous plasma 
were also performed on 13 granulocyte concentrates 
prior to storage. Importantly, the pH remained above 7.0 
only when dexamethasone-mobilized granulocytes were 
diluted 1-in-8, and when G-CSF + dexamethasone-mobi-
lized granulocytes were diluted 1-in-16, an operationally 
Table 1 Selected list of genes regulating neutrophil function
Based on current knowledge, a panel of genes was selected that have been shown to contribute to neutrophil function in health and/or disease states. A brief 
description of the main function of each gene product in neutrophil homeostasis is provided
Gene Role(s) in neutrophil homeostasis
CD177 NB1 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein expressed exclusively by neutrophils, metamyelocytes and myelo-
cytes
SOD1 The SOD1 gene encodes superoxide dismutase-1, a major cytoplasmic antioxidant enzyme that metabolizes superoxide radicals to 
molecular oxygen and hydrogen peroxide. CD177 is upregulated in various inflammatory settings, including bacterial infections. 
Heterophilic PECAM1/CD177 interactions affect the phosphorylation state of PECAM1, as well as endothelial junction integrity and 
neutrophil transmigration
CD64 CD64 is the gene encoding human FcγRI (FCGR1), a glycoprotein that is constitutively expressed on human monocytes and mac-
rophages and that plays a pivotal role in the immune response
FCGR3B The Fc receptor with low affinity for IgG (CD16b) encodes a glycosylphosphatidylinositol (GPI)-anchored protein that is expressed 
constitutively by neutrophils
ELANE Neutrophil elastase is a serine protease of neutrophil and monocyte granules, with key physiologic roles in innate host defense
MPO Myeloperoxidase is a lysosomal protein located in the azurophilic granules of polymorphonuclear leukocytes and monocytes. MPO is 
responsible for microbicidal activity against a wide range of organisms
LYZ Lysozyme catalyzes the hydrolysis of certain mucopolysaccharides of bacterial cell walls
CEACAM8 (CD67) Neutrophil surface protein that is attached to the membrane via a glycosylphosphatidylinositol anchor. In neutrophils, the CEACAM8 
gene is primarily detected in the secondary cytoplasmic granules, but it can also be found in lower amounts on the plasma mem-
brane. The amount of surface CD67 is upregulated upon granulocyte activation
CD62L Homing receptor for lymphocytes to enter secondary lymphoid tissues via high endothelial venules
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impractical condition given the high volume of autolo-
gous plasma needed. This study strongly suggests that 
clinical-grade granulocyte preservative solutions are 
needed to maintain pH during storage.
Neutrophil chemotaxis and NADPH oxidase activity 
were also examined after apheresis collection and neutro-
phil storage to 48 h [34]. After in vivo mobilization with 
G-CSF, neutrophils were collected and stored in apher-
esis bags, with or without additional G-CSF. Neutrophil 
baseline chemotaxis and NADPH activity were preserved 
to 24 h of storage and were not affected by exogenously 
added G-CSF, indicating that biochemical integrity for 
oxidase activity is maintained during short-term storage.
Overall, commercial leukocyte storage solutions can 
prolong granulocyte survival up to 7  days. However, 
testing of granulocytes with monoclonal antibodies or 
alloantibodies is problematic after 4 days due to nonspe-
cific staining.
Fig. 1 Abundance of selected transcripts in leukocytes from donors receiving G-CSF. This dataset (http://www.ncbi.nlm.nih.gov/sites/
GDSbrowser?acc=GDS2959) was selected among studies currently available in NCBI’s Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.
gov/sites/GDSbrowser). In curated datasets, the ‘Data Analysis Tools’ button allows the user to gain access to gene expression levels by directly 
providing the gene name or symbol. Within non-curated datasets, the GEO2R tool allows the user to select a gene platform and to compare two or 
more groups of samples in order to identify genes that are differentially expressed across experimental conditions. This study analyzed the genome-
wide patterns of gene expression with DNA microarrays (Affymetrix Human Genome U133 Plus 2.0 Array) in five healthy donors given G-CSF [25]. 
The expression levels of antigens relevant for granulocyte function are shown. Data were compared with the Mann–Whitney U test. A p value <0.05 
was considered to denote statistical significance
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Clinical trials of granulocyte transfusions
Children
Infections in neutropenic patients are associated with a 
severe prognosis, despite treatment with broad-spectrum 
antibiotics. In children with malignancy and septic shock, 
mortality can be greater than 40 % [35] or even higher, up 
to 85 %, in specific patient subpopulations, such as bone 
marrow transplant recipients with invasive aspergillosis 
[8]. Use of G-CSF and recent improvements in apher-
esis techniques allow the collection of large quantities 
of granulocytes, which result in increases in granulocyte 
counts in the transfusion recipients, particularly in chil-
dren [36]. The main criteria for the clinical use of GTX 
in children have included the presence of severe neutro-
penia with absolute neutrophil counts <0.5 × 109/L [37–
41], 0.2 × 109/L [42] or 0.1 × 109/L [43], associated with 
documented severe infection, not responsive to broad-
spectrum antibiotics and/or antifungal treatments. 
Published and ongoing clinical trials in children are sum-
marized in Table 2.
To date, there have been no randomized controlled 
GTX trials in children, and most available data are derived 
from observational studies [44]. Sachs et  al. assessed 
the feasibility, safety and efficacy of early-onset G-CSF-
mobilized GTX in an open, single-center, and prospective 
phase II clinical trial in immune-compromised children 
with neutropenia and severe infections, who failed to 
respond to broad-spectrum antibiotics [41]. The study 
utilized granulocytes collected from community donors 
and which were crossmatch compatible with the recipi-
ents’ serum. Twenty-seven children at high risk of infec-
tion-related mortality were treated between 2000 and 
Fig. 2 Abundance of selected transcripts in leukocytes from donors receiving G-CSF and dexamethasone. This dataset was selected among studies 
currently available in NCBI’s Gene Expression Omnibus (GEO; http//www.ncbi.nlm.nih.gov/sites/GDSbrowser?acc=GSE12841). Granulocytes were 
isolated from three individuals before and 18 h after treatment with G-CSF and dexamethasone. Some of the control cells were cultured overnight 
in HBSS medium with or without the addition of G-CSF and dexamethasone. Total RNA from each experimental condition was compared to pooled 
RNA of control granulocytes. The genome-wide pattern of gene expression was analyzed with DNA microarrays (Agilent-012391 Whole Human 
Genome Oligo Microarray G4112A) [23]. Data were compared with the Mann–Whitney U test. A p value <0.05 was considered to denote statistical 
significance
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2004. Some patients also received either G-CSF or GM-
CSF. GTXs were well tolerated, without any pulmonary 
transfusion reactions due to alloimmunization. Twenty-
five of 27 patients cleared their initial infection. All six 
patients with invasive aspergillosis showed clinical and 
radiological improvement [41]. A noteworthy finding in 
this study was the remarkable response rate, probably due 
to the early initiation of GTX, i.e., after a median infec-
tion period of 6  days (range 3–18  days), compared with 
8 days (range 1–28 days) [45], 12 days (range 2–36 days) 
[46], and 12 days (range 5–28 days) in other studies [43].
A retrospective analysis including 13 children with 
neutropenia and proven or suspected infection also sup-
ports the efficacy of granulocyte transfusions. Although 
short-term survival was promising, eight of the 13 
patients ultimately died of their infection [47]. In another 
study of 35 children with high-risk febrile neutropenia or 
with granulocyte function defects, GTX were given for 
3 consecutive days. The mean granulocyte content per 
concentrate was 27.4  ×  109. Infection-related survival 
and overall survival rates were 82 and 77 %, respectively, 
at day 30 [40]. Another retrospective study in children 
with febrile neutropenia or defective granulocyte func-
tion [40], who were given GTX for 3 consecutive days, 
showed overall survival rates of 77 and 63 %, respectively, 
at day +30 and +90 after GTX.
A 59  % overall survival rate was obtained in a cohort 
of 32 children, with particularly favorable results in bac-
terial infections (8/11 patients with documented bacte-
rial infection survived) and fungal infection (4/6 patients 
with documented fungal invasive infection survived) 
[39]. In another case series, 13 children with sepsis who 
received 14 courses of GTX were reported to have a good 
short-term survival (12/14 courses, 86 %), whereas long-
term outcome remained dismal (5/13 patients, 39 %) [47].
Seidel et al. [42] showed that neither body weight nor 
granulocyte dose impacted on infection outcome and 
survival in pediatric patients. Nonetheless, this study 
suggested that a tight schedule with daily transfusions 
of at least 1.4  ×  108 granulocytes/kg likely contributed 
better clinical outcomes. This minimum recommended 
dose was derived from a Cochrane meta-analysis [48]. 
They also reported the effect of daily GTX over at least 
5 days containing a minimum of 3 × 108/kg neutrophils 
per concentrate was able to generate a stable ANC incre-
ment, to shorten the duration of neutropenia, and to 
support the control of infections in neutropenic patients 
with high-risk infections.
Granulocyte transfusion therapy has been used in three 
patients with chronic granulomatous disease (CGD) 
and disseminated invasive aspergillosis. Healthy donors 
were mobilized with 450 µg G-CSF and dexamethasone 
approximately 12  h before collection. Patients received 
between 0.4 and 3.0 ×  109/kg granulocytes. Two out of 
three patients survived the infectious episode [49].
Some studies also suggest a role for granulocyte 
transfusions in preventing infections or progression of 
infections in children who are expected to experience 
prolonged neutropenia after HSCT or chemotherapy 
[39, 50]. Granulocyte transfusions from family volunteers 
were used prior to allogeneic HSCT in three children 
with poorly controlled bacterial or fungal infections. No 
transfusion-related reactions and no flares of the infec-
tion were observed. All HSCT procedures were success-
ful [50].
Concern for potentially serious pulmonary compli-
cations is one of the major limiting factors for the rou-
tine use of GTX. Some studies of GTX recipients have 
documented acute pulmonary transfusion reactions 
with shortness of breath, dyspnea, hypoxemia, and lung 
edema [38, 43, 45, 51]. In a Cochrane meta-analysis 
(see also below), adverse events occurred in 15 % of the 
transfusions that had been collected by apheresis, but no 
reactions occurred in pre-medicated patients receiving 
granulocytes collected by apheresis. [48]. Moreover, the 
procedure of HLA-matching of the granulocyte donor 
and GTX recipient in a tight schedule of therapeutic 
GTX, as in Seidel’s prospective study [42], might carry 
the disadvantage of delayed treatment or lower granulo-
cyte dosage.
Although randomized controlled trials are not available 
in children yet, the current evidence supports the early 
use of GTX, especially for patients with bacterial infec-
tions. However, patients should be closely monitored for 
adverse pulmonary transfusion reactions.
Adults
Published and ongoing clinical trials in adults are sum-
marized in Table  3. A meta-analysis published in 1997 
reviewed eight randomized controlled trials conducted 
between 1970 and 1995 and were designed to assess the 
efficacy of prophylactic granulocyte transfusions [5]. The 
results suggested that daily prophylactic transfusions of 
compatible granulocytes could reduce the risk of bacte-
rial or fungal infection, death or death from infection in 
patients with severe neutropenia. The study found that 
both granulocyte dose and granulocyte compatibility were 
determinants of the efficacy of granulocyte transfusions.
A community blood bank GTX program was devel-
oped at the Fred Hutchinson Cancer Research Center. 
Donors received G-CSF and dexamethasone. This pro-
gram treated 19 patients with documented fungal or 
antibiotic resistant bacterial infections who were either 
waiting for or recently given HSCT [52]. Adverse reac-
tions occurred in 7  % of the transfusion episodes, with 
no clear relationship with the presence or development 
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of leukocyte antibodies. Overall, infection resolved in 8 
patients. However, none of the 5 patients with aspergil-
losis cleared their infection.
In another study G-CSF-mobilized GTX collected 
from related donors were administered to 15 neutro-
penic patients with hematologic malignancies and fungal 
Table 3 Clinical trials in adults
Completed and ongoing clinical trials of therapeutic granulocyte transfusions in adults are summarized
HSCT hematopoietic stem cell transplantation, DXM dexamethasone, OS overall survival, ORR overall response rate
# of pts Study type Indications for GTX Remarks/outcome Reference(s)
22 Retrospective Grade IV febrile neutropenia G-CSF only for neutrophil mobilization; 
when >1010 PMNs were infused, clinical 
benefit compared with historical controls
[89]
11 Case series Invasive Fusarium infection Ninety-one percent response rate [57]
74 Retrospective Treatment of infections In 34 patients (46 %), GTXs were discontin-
ued due to clinical response and neutrophil 
count recovery
[12]
56 Retrospective Severe infection in SAA GTX + G-CSF; Survival at 30, 90 and 180 days 
was 89, 70 and 66 %, respectively. Survival 
rate correlated with hematopoietic 
recovery
[58]
24 Retrospective Invasive opportunistic infections GTX + IFN-γ1b + G-CSF or GM-CSF. 60 % 
ORR 4 weeks after treatment
[87]
25 Prospective Progressive uncontrolled infections Donors given G-CSF and dexamethasone, 
either alone or in combination. Favorable 
responses in 40 % of patients (especially in 
those with fungal or Gram-negative infec-
tions). One death from severe pulmonary 
reaction
[51]
20 Pilot Neutropenia refractory to G-CSF Favorable response in 8 out of 15 assessable 
patients (53 %)
[53]
19 Phase I/II Infections after HSCT GTXs from community donors (94 %). 
G-CSF + dexamethasone. Resolution of 
infection in 8/19 patients (42 %). Overall, 
four of the 19 patients were alive on day 
30 after HSCT. None of the patients with 
invasive aspergillosis (n = 5) cleared the 
infection
[52]
30 Retrospective Neutropenia and severe infections G-CSF + dexamethasone. In 11 patients, 
resolution of infection could be related to 
granulocyte transfusions. Three of these 
patients became long-term survivors
[54]
52 Prospective Control or prevention of severe infections Control of infections was achieved in 82 % of 
life-threatening episodes. No reactivation 
of infections occurred under prophylactic 
granulocyte transfusions
[55]
100 Randomized (GRANITE study) Febrile neutropenia Ongoing national, multi-center trial; 
Patients aged 1–75 years (www. drks.de/
DRKS00000218); Date of first enrollment: 
October 2014; Arm 1 (intervention-group): 
transfusion of standardized leukapheresis 
products of granulocytes on every other 
day + standard therapy; arm 2 (control 
group): standard-therapy without granulo-
cyte transfusions
NA
30 Prospective (GIN1 study) Febrile neutropenia Granulocytes derived from whole blood; risk 
of adverse events comparable to other 
granulocyte components; recovery of neu-
trophils and survival in all patients except 
for two adult patients who died
[26]
114 Randomized (RING study) Febrile neutropenia Composite endpoint was survival + micro-
bial response 42 days after randomization; 
42 and 43 % success rates for the granulo-
cyte and control groups, respectively
NCT00627393; [56]
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infections [53]. Eleven patients had favorable responses 
and eight of them remained free of infection 3  weeks 
after therapy.
In a similar study, thirty patients with hematologi-
cal malignancies received granulocyte transfusions for 
neutropenia and severe infections during a 12-year 
period [54]. The donors were given G-CSF and intrave-
nous dexamethasone. A median of 3 transfusions was 
administered to the patients. For 11 patients (37  %), 
defervescence and resolution of signs of infection could 
be attributed to granulocyte transfusions. Mortality at 
30 and 180  days after granulocyte transfusions was 40 
and 72  %, respectively. No infection-related mortality 
was reported in patients who responded clinically to the 
granulocyte transfusions.
A prospective, non-randomized study evaluated the 
efficacy of granulocyte transfusions for controlling and 
preventing recurrence of severe infections in patients 
with hematological malignancies [55]. Fifty-two patients 
were enrolled between 1997 and 2003, with a total of 67 
infectious episodes. The underlying infections were pre-
dominantly of fungal origin. In the interventional group, 
a favorable response was documented in 82  % of the 
infectious episodes, especially in patients with bacterial 
infections. In the prophylactic group, no single reactiva-
tion of a previous infection occurred. Survival at day 100 
after granulocyte transfusions was 64 and 65  % in the 
interventional and prophylactic group, respectively. With 
a median follow-up of 3.5 years, 42/52 patients had died, 
mostly due to the underlying progressive disease.
The RING study is a recently completed randomized 
controlled study carried out by the NHLBI Transfusion 
Medicine/Hemostasis Clinical Trials Network which 
evaluated the efficacy of high-dose granulocyte trans-
fusion therapy [56]. The desired sample size was 236 
subjects, in order to have 80  % power to detect a 20  % 
difference in success rates between the treatment and 
control groups. Fourteen clinical sites participated and 
114 subjects were enrolled. Patients were neutropenic 
and had a proven/probable/presumed bacterial or fun-
gal infection. Subjects were randomly assigned to receive 
standard antimicrobial therapy with or without GTX 
collected from normal donors stimulated with G-CSF 
and dexamethasone. The median number of granulo-
cytes administered per transfusion was 54.9 ×  109. The 
composite primary endpoint was survival plus a micro-
bial response evaluated 42 days after randomization. The 
median number of transfusions in subjects randomized 
to the GTX arm was five. Success rates were 42 % (20/48) 
and 43 % (21/49) for the granulocyte and control groups, 
respectively, on intention-to-treat analysis, and 49  % 
(17/35) and 41  % (16/39), respectively, on per-protocol 
analysis. Because of low accrual, the power of this study 
to detect a 20 % difference in the overall success rates was 
reduced to approximately 40 %. Thus, it cannot be ruled 
out that a true effect was missed, particularly if the effect 
is limited to specific patient subsets [56].
A retrospective analysis of 74 patients with refractory 
hematological malignancies, receiving granulocyte trans-
fusions, showed that patients with documented severe 
infections might have better survival rates compared with 
those who do not have severe infection [12]. Patients who 
died by 12 weeks after granulocyte transfusion initiation 
were more likely to have leukemia and not to have had 
recovery of neutrophil counts. Furthermore, the use of 
G-CSF and IFN-γ as adjuvant therapy were more com-
mon in patients who survived the infectious episode. This 
observation may suggest that the benefits of granulocyte 
transfusions are greater in the presence of documented 
severe bacterial or fungal infection. Importantly, these 
survival benefits were only observed when GTX were 
administered prior to disease progression and multisys-
tem failure, requiring the use of mechanical ventilation in 
critical care units.
A recent single-center case series of 11 patients with 
invasive Fusarium infections who were treated with 
GTX showed a 91  % response rate [57]. Three patients 
who failed to achieve hematopoietic recovery did not 
survive, implying that GTX may improve response rates 
by bridging periods of neutropenia or bone marrow 
suppression.
Granulocyte transfusions have been combined with 
G-CSF administration in 56 patients with severe aplastic 
anemia and severe infections [58]. The median number of 
granulocyte components transfused was 18; survival at 
30, 90 and 180  days were 89, 70 and 66  %, respectively. 
Among the 31 patients with invasive fungal infections, 
survival at 30 days, 90 days and 180 days was 87, 58 and 
52 %, respectively. Among the 25 patients with refractory 
severe bacterial infections, survival at 30, 90 and 180 days 
were 92, 84 and 84 %, respectively. Importantly, survival 
rate was correlated with hematopoietic recovery. This 
study suggests that granulocyte transfusions combined 
with G-CSF could be an adjunctive therapy for treating 
severe infections in patients with severe aplastic anemia.
It has been shown that accumulation of the transfused 
granulocytes at sites of infection can help predict the 
clinical response. In four patients given 99mTc-HMPAO- 
labeled granulocytes, planar imaging at 1 h (early) and 4 h 
(delayed) after granulocyte infusion allowed the identifi-
cation of responders and non-responders based on gran-
ulocyte uptake, as assessed by the lesion-to-normal lung 
ratio. By contrast, granulocyte scintiscans of two patients 
who were non-responders did not show any granulocyte 
uptake into the infiltrative lung lesions [59].
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The clinical results of the transfusion of granulocytes 
collected from community donors vs. family donors may 
be similar [60]. The use of granulocytes collected from 
community donors bears the advantage of requiring less 
time to begin the GTX course. In addition, higher incre-
ments of the absolute neutrophil count were recorded 
in patients receiving GTX from G-CSF and dexameth-
asone-stimulated community donors, compared with 
patients receiving GTX from G-CSF-stimulated family 
donors. Overall, 57 and 56 % of patients receiving granu-
locytes collected from unrelated community and related 
donors, respectively, had a progressive or fatal course of 
infection.
Collectively, the available evidence points to the effi-
cacy of GTX as an adjunct treatment modality for 
severely neutropenic patients who are likely to experi-
ence hematopoietic recovery.
Evidence from the Cochrane Library
The Cochrane Library provides high-quality informa-
tion based on publication types that are crucial in evi-
dence-based medicine [61]. The Cochrane Database of 
Systematic Reviews (CDSR) is the primary output of the 
Cochrane Collaboration. The Cochrane Library differs 
from PubMed, in that it is a pre-filtered resource that 
only contains specific publication types (randomized 
clinical trials/controlled clinical trials in CENTRAL, 
systematic reviews in Cochrane Database of Systematic 
Reviews (CDSR) and Database of Abstracts of Reviews 
of Effects (DARE). The Cochrane Library offers similar 
search features as PubMed, e.g. usage of MeSH, limit-
ing the search to specific databases or publication dates, 
saving of searches, and setting up alerts in a personal 
account.
The Cochrane Collaboration has published two reviews 
that aim to appraise the literature for randomized con-
trolled trials on granulocyte transfusions for prevent-
ing and treating infections in patients with neutropenia 
or neutrophil dysfunction [48, 62]. In the prevention 
setting, ten randomized clinical trials were identified 
that assessed the safety and effectiveness of prophylac-
tic transfusions [62]. Eight trials were undertaken in the 
US, one in Spain and one in the UK. All the studies but 
one were published between 1978 and 1987. Donors 
were given either steroids or no form of medication. 
G-CSF was used in only one trial, published in 2006. 
Although the summary results for mortality, mortality 
due to infection and data on episodes of infection failed 
to reach statistical significance, there were consistent 
trends in favor of the intervention [62]. When the tri-
als collecting <1 × 1010 granulocytes were excluded, the 
relative risk ratio was significantly in favor of the inter-
vention. The authors conclude that the review identified 
a reduction in mortality due to infection in children and 
a transfusion with >1 × 1010 granulocytes. However, the 
studies were published many years ago and supportive 
care measures have significantly improved over time. 
This Cochrane review, first published in 2009, has been 
recently updated [63]. Twelve trials met the inclusion 
criteria. One trial was ongoing at time of publication of 
the updated analysis (https://clinicaltrials.gov/ct2/show/
NCT01204788), leaving a total of 11 trials eligible involv-
ing 653 participants. Ten studies included only adults, 
and two studies included children and adults. Overall, 
the quality of the evidence was judged to be very low 
or low across different outcomes according to GRADE 
methodology. All-cause mortality was reported for nine 
studies (609 participants) and mortality due to  infec-
tion  was reported for seven studies (398 participants). 
There was no difference in all-cause mortality meas-
ured over 30  days between patients receiving prophy-
lactic  granulocyte  transfusions and those that did not. 
Similarly, mortality due to infection over 30  days was 
not different in patients receiving granulocyte transfu-
sions and in those that did not. In the low-dose granu-
locyte group (<1.0 × 1010 granulocytes/day), the number 
of patients with infection was similar in the two patient 
groups. However, the number of patients with infec-
tion was lower among recipients of intermediate doses 
of granulocytes (1.0–4.0  ×  1010/day). Also, the number 
of patients with bacteremia and fungemia was lower 
among recipients of prophylactic granulocyte transfu-
sions. This systematic review concluded that there is 
low-grade evidence that prophylactic granulocyte  trans-
fusions decrease the risk of bacteremia or fungemia. 
Similarly, there is low-grade evidence that the effect of 
prophylactic granulocyte transfusions is dose-dependent, 
with doses of at least 1.0 × 1010/day being more effective 
at decreasing the risk of  infection. Collectively, there is 
insufficient evidence to determine any difference in mor-
tality rates due to infection, all-cause mortality, or serious 
adverse events.
A third Cochrane review included eight randomized 
clinical trials, published between 1975 and 1984 [48]. 
Eight studies were conducted in the US, one in Canada; 
one in Switzerland and one was a multicenter European 
study. Overall, 149 patients were available for analysis 
in the intervention arm. In these trials no granulocytes 
were collected after the administration of G-CSF and/
or steroids. The method of granulocyte procurement 
also differed, being filtration leukapheresis in three stud-
ies, discontinuous flow centrifugation in two studies and 
continuous flow centrifugation in the remaining three 
studies. The evidence from the eight randomized clinical 
trials (RCTs) was considered to be inconclusive to sup-
port or refute the use of granulocyte transfusions for the 
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treatment of severe infections in neutropenic patients. 
Although the statistical heterogeneity and clinical diver-
sity of the eight studies may have affected the clinical 
outcome, there may be a survival benefit for patients 
administered >1 × 1010 granulocytes.
Alloimmunization following GTX
The efficacy of granulocyte transfusions may be lower 
in patients with HLA alloimmunization. A retrospective 
study of alloimmunization to HLA and neutrophil anti-
gens was performed in 18 patients with chronic granu-
lomatous disease (CGD), who had also received repeated 
granulocyte transfusions. Sera were tested using lym-
phocytotoxicity, granulocyte agglutination, granulocyte 
immunofluorescence, monoclonal antibody immobiliza-
tion of granulocyte antigen, and immunoprecipitation 
assays. This study showed that sera from 14 of the 18 
transfused patients contained WBC antibodies. Seven 
serum samples reacted in the lymphocytotoxicity, gran-
ulocyte immunofluorescence, and granulocyte aggluti-
nation assays; seven reacted in the lymphocytotoxicity 
and granulocyte immunofluorescence assays, but not the 
granulocyte agglutination assay, and four did not react. 
Overall, antibodies to neutrophil antigens other than 
HLA molecules could be detected in sera from eight 
patients. When the monoclonal antibody immobiliza-
tion of granulocyte antigen assay was employed, three 
sera samples reacted with Fcγ receptor III (CD16), three 
with the 58- to 64-kDa protein carrying the neutrophil 
antigen NB1, one with CD11a, and one with CD18. In 
addition, antibodies from three patients were shown to 
immunoprecipitate a 60-kDa neutrophil protein. Trans-
fusion reactions, including pulmonary toxicity, were 
documented in 11 of the 14 patients with WBC anti-
bodies, but in none of the 4 patients without antibodies. 
The patients with WBC antibodies were given a higher 
number of granulocyte concentrates. This study shows 
that recipients of granulocyte transfusions often develop 
alloimmunization and suggests that screening studies for 
WBC antibodies are indicated periodically during trans-
fusions, after any adverse reactions, or before subsequent 
transfusion cycles. If WBC antibodies are present, no 
further granulocyte transfusions should be given unless 
the granulocytes are collected from HLA- and/or neutro-
phil antigen-compatible donors [64].
Dihydrorhodamine-123 (DHR) is a marker for cellular 
NADPH oxidase activity and has been used to monitor 
the survival of transfused oxidase-positive granulocytes 
[65]. This technique is based on the ability of normal 
granulocytes to oxidize the non-fluorescent dye DHR to 
the fluorescent rhodamine-123 through the respiratory 
burst. Because patients with CGD have granulocytes that 
lack NADPH oxidase, any fluorescing granulocytes are of 
donor origin. Eight out of ten HLA alloimmunized CGD 
patients receiving granulocyte transfusions experienced 
adverse reactions, ranging from chills and/or fever to res-
piratory compromise. The average recovery of oxidase-
positive granulocytes was approximately 1 and 20  % in 
patients with or without HLA allosensitization, respec-
tively. Greater than 1 % in vivo recovery of DHR-enhanc-
ing donor granulocytes was correlated with lack of HLA 
alloimmunization. In five patients, the granulocyte trans-
fusions were discontinued because of severe transfusion 
reactions. Overall, nine of ten patients cleared the infec-
tion. This study suggests that if HLA antibodies are pre-
sent and the survival of donor granulocytes, as detected 
by DHR analysis, is low, granulocyte transfusions should 
be discontinued, as the potential benefits are outweighed 
by the risks.
Adverse effects of granulocyte transfusions
Several studies reported high rates of transfusion reac-
tions after the administration of granulocyte concen-
trates. Severe pulmonary reactions might be attributed 
to sequestration of the transfused cells into the pulmo-
nary vascular bed. Most transfusion reactions have been 
documented in patients who were alloimmunized to leu-
kocyte antigens. Anti-leukocyte antibodies could affect 
post-transfusion increments of neutrophil counts, alter 
the kinetics of circulating neutrophils and limit the anti-
microbial effects of granulocyte transfusions. Impor-
tantly, no significant complications from the transfusions 
were reported in three RCTs that provided compatible 
leukocytes [66–68].
Ethical and safety issues related to G‑CSF 
administration to healthy donors
G-CSF effects in healthy volunteers, although normally 
transient and self-limiting, are currently believed to be 
more complex and heterogeneous than previously appre-
ciated. In addition to its established role in activating 
neutrophil kinetics and functional status, G-CSF admin-
istration can affect monocyte/DC and lymphocyte num-
bers and/or function, as well as the hemostatic system 
[69–71]. In vivo studies have shown that G-CSF levels 
in the peripheral blood following G-CSF administration 
peak at 4  h after injection and return to baseline levels 
after 2  days [20, 72]. Although short-lived, the increase 
of blood G-CSF levels exceeds the levels that are found in 
patients with respiratory or bacterial infection [73].
The available clinical data do not provide unequivocal 
evidence that G-CSF can transform normal hematopoi-
etic stem cells in the absence of predisposing factors. 
In patients with acute myeloid leukemia (AML) with 
altered proportions of G-CSF receptor isoforms, G-CSF 
may promote the survival of leukemic cells. In severe 
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congenital neutropenia and severe aplastic anemia, 
G-CSF receptor mutations or alterations in the propor-
tions of specific isoforms in some patients appear to ren-
der them susceptible to leukemic transformation in the 
presence of sustained pharmacologic levels of G-CSF [74, 
75]. Nevertheless, the theoretical possibility that G-CSF 
could increase the risk of developing leukemia in stem 
cell donors exists.
A review of data from  >50,000 healthy donors given 
G-CSF was recently published and documented no 
evidence for an increased incidence of hematological 
malignancies [73]. Some studies specifically addressed 
this issue in granulocyte donors, who may be exposed 
to multiple doses of G-CSF, repeatedly over subsequent 
mobilization cycles. In one of these reports, donors who 
had received G-CSF three or more times for granulocyte 
apheresis between 1994 and 2002 were matched with 
control platelet donors for sex, age, and approximate 
number of donations [76]. Eighty-three donors contrib-
uted to 1,120 granulocyte concentrates. With a median 
follow-up of 10 years, there were seven predefined health 
events, including malignancies, coronary artery disease 
and thrombosis, in granulocyte donors and five in platelet 
donors, suggesting that G-CSF/dexamethasone stimula-
tion is safe. A second paper addressed whether repeated 
administrations of G-CSF produce monosomy-7 aneu-
ploidy in healthy donors [77]. Chromosomes 7 and 8 were 
analyzed by fluorescent in  situ hybridization (FISH) in 
CD34+ cells from 35 healthy donors after G-CSF admin-
istration for 5  days and by spectral karyotyping analysis 
(SKY) in four individuals to assess chromosomal integrity. 
The authors also examined 38 granulocyte donors who 
received up to 42 doses of G-CSF and dexamethasone. 
No abnormalities in chromosomes 7 and 8 were found 
in G-CSF-mobilized CD34+ cells and no aneuploidy was 
detected in G-CSF/dexamethasone-treated donors.
The influence of G-CSF on DNA methyltransferase 
(DNMT) activity and on changes in DNA methylation of 
candidate genes has been analyzed in peripheral blood 
cells of 20 healthy unrelated stem cell donors within an 
observation period of 1 year [78]. The authors performed 
methylation-specific PCR to detect the methylation sta-
tus of promoter CpG islands of retinoic acid receptor β 
(RAR-B) gene and Ras association domain family 1A 
(RASSF1A) gene. Although DNMT activity increased sig-
nificantly on the day of donation and 1 day after, baseline 
values were reached by day +7. In addition, differences in 
the gene methylation of RAR-B and RASSF1A were not 
detected between both groups, suggesting no long-last-
ing increase of DNMT activity or enhanced DNA meth-
ylation after G-CSF treatment.
The immunological alterations induced by G-CSF 
mobilization were prospectively analyzed in 24 healthy 
donors [79]. Interestingly, platelet, granulocyte, mono-
cyte, B cell, and DC counts, as well as IL-2, IL-8, and 
IL10 secretion, perturbed at time of G-CSF mobilization, 
returned to baseline values at 1  month, with T-cell and 
NK cell counts recovering at 3  months. In vitro immu-
noglobulin production was increased up to 6  months 
after mobilization. Although some immunologic param-
eters may be altered in a more persistent manner than 
initially believed, most alterations remain transient with 
restoration of normal values by 1  year. We have shown 
that G-CSF can perturb mitochondrial function and pro-
mote T-cell activation-induced apoptosis through the 
upregulation of Bax [70]. These abnormalities could be 
counteracted in  vitro through the use of an anti-CD95 
monoclonal antibody.
A recent report identified 8 longitudinal studies on 
the incidence of AML among healthy donors mobilized 
with G-CSF [75]. In aggregate, 40,717 donors provided 
151,016 donor-years of follow-up with 3 cases of AML 
identified, corresponding to an incidence rate of 2 per 
100,000 donor-years, based upon the overall reported 
IR of 3.5 per 100,000 person-years in the United States 
(SEER data, 2004–2008). However, the latent period of 
secondary AML is long and the incidence of AML in the 
general population is extremely low, implying that at least 
10 years of follow-up of more than 2000 peripheral blood 
stem cell donors would be required to detect even a ten-
fold increase in AML. Thus, an adequately designed and 
powered study should be performed. It also needs to be 
considered that HLA-identical sibling donors for patients 
with leukemia may be themselves predisposed to develop 
the disease.
Finally, a recent survey on 83 donors who contributed 
1120 granulocyte concentrates suggests that G-CSF/
dexamethasone stimulation may be safe [76, 80]. This 
study identified donors who had received G-CSF three or 
more times for granulocyte apheresis, between 1994 and 
2002, and matched them with control platelet donors. 
There was no difference in blood cell counts between the 
granulocyte donors and the control platelet donors. Also, 
no differences were recorded in the occurrence of pre-
defined health events, including malignancies, coronary 
artery disease, and thrombosis, between the two groups 
of donors. At a median 10-year follow-up, there were 
seven such events in the granulocyte donors and five in 
the platelet donors.
Based on of an assessment of a continuing lack of evi-
dence for an increased risk of malignancy in donors 
receiving G-CSF, the WMDA issued a statement in 2012, 
which endorses that, ‘Studies following large numbers of 
unrelated donors have shown that the risk of developing 
cancer within several years after the use of G-CSF is not 
increased compared with donors not receiving G-CSF’ 
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[73]. It is recommended that donors be asked about a 
family history of leukemia and be offered a long-term 
follow-up. The statement from WMDA relates to donors 
who have received ‘originator product G-CSF’ (Neupo-
gen®, Filgrastim, Amgen) and does not necessarily apply 
to other mobilizing agents.
Cytokines and combination strategies to prevent/
treat infections
IL-8 is a pro-inflammatory chemokine that can mobilize 
hematopoietic stem cells in mice and monkeys. In non-
human primates, IL-8 with a dose range of 30–50 μg/kg 
of body weight induces a 8.7-fold increase of blood neu-
trophils with peak counts being achieved 45  min after 
injection. IL-8-mobilized granulocytes were functionally 
normal, in spite of decreased chemotaxis and adherence 
abilities, as well as H2O2 production index. This study 
suggests that IL-8-induced neutrophils could be used for 
transfusion purposes [81].
Cytokines such as GM-CSF, M-CSF and IFN-γ have 
been used to treat specific infections [82]. GM-CSF 
induced complete clearance of fungal infections in 6 of 
8 evaluable patients receiving amphotericin-B and GM-
CSF [83]. Responses were similarly favorable in patients 
with bacterial infections. M-CSF has been used in addi-
tion to standard anti-fungal drugs to treat infectious 
complications after allogeneic HSCT, with responses 
observed in 6 of the 24 treated patients [84]. A long-term 
follow-up study of 46 consecutive HSCT recipients at 
The Fred Hutchinson Cancer Research Center observed 
a 27 % overall survival in patients given 100-2,000 µg/m2 
M-CSF from day 0 to 28 after determination of progres-
sive fungal disease, compared with 5 % in 58 similar his-
torical controls [85]. The survival advantage was entirely 
because of a 50 % survival rate in patients with Candida 
infection and Karnofsky scores greater than 20 %. M-CSF 
was well tolerated, although patients receiving higher 
doses experienced a reduction in platelet counts. IFN-γ 
has been administered twice weekly to 128 patients 
with CGD [86]. In this study, the IFN-γ-treated group 
developed significantly fewer infections compared with 
patients receiving placebo.
IFN-γ1b has been administered concomitantly with 
granulocyte transfusions to enhance the host defense 
against fungal pathogens [87]. In this retrospective study, 
20 patients mostly with proven or probable invasive fun-
gal infections received high-dose granulocyte transfu-
sions and a median of 9 doses of IFN-γ1b. Most patients 
also received G-CSF or GM-CSF during combined treat-
ment with granulocytes and IFN-γ1b. Four weeks after 
the commencement of therapy, 45 % of patients had com-
plete or partial resolution of infection, whereas another 
3 patients (15  %) experienced infection stabilization. 
The 60 % overall response rate observed in this study is 
encouraging and prompts the evaluation of this com-
bined therapeutic strategies in patients with invasive 
fungal infections. Enhancement of the microbicidal activ-
ity of granulocytes by IFN-γ1b may be attributed to up-
regulation of MHC class II, improved ex  vivo survival 
of granulocytes and increased generation of superoxide 
through the degradation of intracellular tryptophan.
It has been shown that the elevation of intracellu-
lar phosphatidylinositol (3,4,5)-triphosphate signaling 
with PTEN inhibitor SF1670 can enhance the efficacy of 
granulocyte transfusions [88]. In mice with thioglycol-
late-induced peritonitis, intravenously injected SF1670 
significantly elevated neutrophil recruitment to the 
inflamed peritoneal cavity. Furthermore, pre-treatment 
with SF1670 increased the efficacy of granulocyte trans-
fusions in a mouse neutropenia-associated bacterial 
pneumonia model, with approximately 40  % of surviv-
ing mice after transfusion with SF1670-pretreated neu-
trophils compared with 10  % of mice transfused with 
untreated neutrophils. Importantly, pre-treatment with 
SF1670 also increased the efficacy of transfusion with 
G-CSF-mobilized neutrophils. SF1670 enhanced fMLP-
elicited signaling and reactive oxygen species production 
in G-CSF-primed neutrophils.
Concluding remarks
Data regarding efficacy and complications of GTX are 
still limited in children. A properly designed, rand-
omized controlled trial of GTX in children with clini-
cally relevant endpoints would help resolve the current 
controversy surrounding the use of GTX in this patient 
population. The heterogeneity of study populations, 
types of infection, antimicrobial therapy and dosage of 
transfused granulocytes, coupled with lack of randomi-
zation, power and outcome parameters make it difficult 
to propose accurate recommendations. In addition, their 
efficacy may be enhanced by cytokine therapy, including 
IFN-γ, GM-CSF and G-CSF. Overall, granulocyte trans-
fusions remain an important therapeutic modality in 
patients with difficult-to-treat opportunistic infections, 
especially as a bridge towards spontaneous recovery of 
neutrophil counts in patients who achieve remission of 
their underlying disease [89].
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